In English | En español

National Cancer Institute

at the National Institutes of Health

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI

Clinical Trials Search Results

Page Options

Email This Document

Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Popular Resources

Help Using the NCI Clinical Trials Search Form
Learn About Clinical Trials
About NCI's List of Cancer Clinical Trials
NCI Dictionary of Cancer Terms
NCI Drug Dictionary

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 27 for your search:

Drug:  perifosine
Find trials that include:  Any drugs shown
Trial Status:  Closed

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: Protocol 343, NCT01097018

Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: Perifosine 218, NCT00401011

Phase II Study of Perifosine as Second-Line Therapy in Patients With Advanced Adenocarcinoma of the Pancreas

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: PMH-PHL-015, NCI-5983, 5983, NCT00053924

Phase II Study of Perifosine in Patients With Recurrent or Refractory, Locally Advanced or Metastatic Breast Cancer

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: PMH-PHL-014, NCI-5982, NCT00054145, 5982

Phase II Study of Perifosine in Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: ECOG-E1202, NCT00059982, E1202

Phase II Study of Perifosine in Patients With Metastatic Androgen-Independent Prostate Cancer

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-03-C-0157, NCI-5970, NCT00060437

Phase II Study of Perifosine in Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: UCCRC-12198A, NCI-5938, 5938, NCT00062387

Perifosine in Treating Patients With Advanced Soft Tissue Sarcoma

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000315381, P30CA015083, MC0276, 5972, MAYO-MC0276, NCI-5972, NCT00064324

Phase II Study of Perifosine in Patients With Refractory and Relapsed Leukemia

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: Perifosine 217, NCT00391560

10.

Efficacy of Perifosine Alone and in Combination With Dexamethasone for Patients With Multiple Myeloma

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: Perifosine 212, NCT00375791

11.

A Trial of Perifosine in Patients With Chemo-Insensitive Sarcomas

Phase: Phase II
Type: Treatment
Status: Completed
Age: 13 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: Perifosine 214, NCT00401388

12.

Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: Perifosine 211, NCT00398879

13.

A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor (TKI) - Failure in Patients With Renal Cancer

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: Perifosne 228, NCT00448721

14.

Ph II Study of Perifosine Plus Gleevec for Patients With GIST

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: Perifosine 210, NCT00455559

15.

Ph II Study of Perifosine for Patients With Carcinoma of the Kidney

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: Perifosine 231, NCT00498966

16.

Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 00015060, NCT00873457

17.

Perifosine in Treating Patients With Metastatic or Recurrent Malignant Melanoma

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: I156, CAN-NCIC-IND156, CDR0000269475, NCIC-156, IND156, NCT00053781

18.

Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: I155, CAN-NCIC-IND155, CDR0000269476, NCIC-155, IND155, NCT00053794

19.

Perifosine in Treating Patients With Recurrent Prostate Cancer

Phase: Phase II
Type: Treatment
Status: Completed
Age: Over 18
Sponsor: NCI, Other
Protocol IDs: CDR0000287195, CCC-PHII-44, CHNMC-PHII-44-02166, NCI-5978, 5978, NCT00058214

20.

Clinical and Molecular-Metabolic Phase II Trial of Perifosine for Recurrent/Progressive Malignant Gliomas

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 06-044, NCT00590954

21.

Phase I Study of Perifosine in Patients With Refractory Solid Tumors, Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Myelodysplastic Syndromes, or Hodgkin's Lymphoma

Phase: Phase I
Type: Treatment
Status: Completed
Age: Over 18
Sponsor: NCI
Protocol IDs: NCI-99-C-0043, NCI-T98-0065, T98-0065, NCT00019656

22.

Phase I Study of UCN-01 in Combination With Perifosine in Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia, or High Risk Myelodysplastic Syndromes

Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSGCC-0507, MSGCC-H-27229-0507, NCI-7311, 7311, NCT00301938

23.

Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: Perifosine 124, NCT00398814

24.

Phase I Study of Perifosine + Lenalidomide and Dexamethasone for Patients With Multiple Myeloma